News

As per the deal, both the companies will advance the product developement while ZMC will fund the ongoing development costs. ZMC will assume the commercialisation rights to the

The Phase IV SAVOR-TIMI-53 cardiovascular outcomes trial was conducted in 16,500 type 2 diabetes patients with either a history of established cardiovascular disease or multiple risk factors, with

Sources familiar with the matter were quoted by Reuters as saying that the $500m-$1bn worth portfolio could be divided and sold to different parties. Without disclosing the estimated

Both the companies will integrate LGC Genomics’ DNA purification solution with Covaris FFPE extraction workflow, which provides a complete solution from FFPE tissue to high quality DNA, suitable

Designed to assess the safety, tolerability and efficacy of CCX140, the randomised, double-blind, placebo-controlled study is being conducted at 90 sites throughout Europe. ChemoCentryx president and chief executive

Lundbeck agreed with each of the nine companies in 2002 to delay the launch of generic medicines of its anti-depressant. Ranbaxy Laboratories was fined more than Rs800m (€10.32m),

The Medicines and Healthcare Products Regulatory Agency (MHRA) has revealed that the company recalled two batches of the asthma drug in amber glass bottles displaying the batch numbers

Targeting peroxisome proliferator activated receptor delta (PPARd), DB959 was developed by DARA through Phase 1 trials for the treatment of diabetes and dyslipidemia. As per the company’s strategic

The US patent is titled ‘Intermediate Compounds and Processes for the Preparation of Tapentadol and Related Compounds’. Using easily available reagents, the patented and cost effective process fitting